

Medical Communication

Status of Various Clinical Attributes and Electrolytes in Oral Cancer Patients from Pakistan

Maria Rana¹, Sikandar Ali Siyal², Amir Bux Detho², Ikram-ul Haq^{1*}, Sikandar Ali Sangrasi³ and Syed Murtaza Ali⁴

¹Institute of Biotechnology and Genetic Engineering (IBGE), University of Sindh, Jamshoro-76080, Pakistan. ²Department of Pathology, Peoples University of Medical & Health Science for Women (PUMHSW), Nawabshah-67480, Pakistan. ³Institute of Physiotherapy and Rehabilitation Sciences, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro-76090, Pakistan. ⁴Institute of Physical Therapy and Rehabilitations Sciences, Peoples University of Medical & Health Science for Women (PUMHSW), Nawabshah-67480, Pakistan.

ABSTRACT

Cancer is a lethal disease and its incidences has been increasing day by day. The survival rates of the cancer patients are lesser due to lack of its awareness, available health facilities and other many socioeconomic conditions to treat it. Various abnormal metabolic and ionic changes occur in throat and mouth cancer patients than healthy persons. In this experiment, with average 36-42 years aged 21 throat and 24 mouth cancer patients were selected to analyze the changes in complete blood counts (CBC), liver functional tests (LFT) and electrolytes. Among the patients, Hb (g/dL) decreased and PLT ($10^8/\mu$ L) increased significantly in both typed cancer patients than normal healthy persons. Higher ALP and bilirubin levels were observed high (p ≤ 0.05), while ALT and urea concentration remained unchanged among the patients to normals. Serum electrolytes i.e. Mg²⁺ was observed higher in patients (p ≤ 0.05), while Cl⁻ and Ca²⁺ were decreased significantly in both throat and mouth cancer patients. The K⁺ mildly increased non-significantly remained within the reference ranges. Changes in biosynthesis of metabolites induces electrolyte imbalanced condition as well as the alterations in HB and PLT may also be caused by imbalanced nutrition-based factors. By early careful monitoring of such indicators in the cancer patients could play a preventive role in cancer disease prognoses.

KEY WORDS: CANCER PATIENTS, ELECTROLYTES, SERUM, CBC, LFTS, PLATELETS.

INTRODUCTION

In the world, the 2nd largest human killer disease is cancer with 25 % of total deaths per year including Pakistan and it has been elevating in numbers continuously (Jemal et al., 2010; Simard et al., 2012; Moore, 2013; Torre et al., 2016; Murray et al., 2020). New cancer incidences are increasing in Asian Pacific regions, while survival rates remained lesser due to lack of cancer awareness, lake of health facilities and other many socioeconomic conditions (Hanif et al., 2009; Begum et al., 2012; Cao et al., 2017;

Article Information:*Corresponding Author: rao.ikram@yahoo.com Received: 03/03/2021 Accepted after revision: 03/06/2021 Published: 30th June 2021 Pp- 668-674 This is an open access article under CC License 4.0 Published by Society for Science & Nature, Bhopal India. Online at: https://bbrc.in/ Article DOI: http://dx.doi.org/10.21786/bbrc/14.2.34 Ashaq et al., 2021). The cancer is the multi-factorial condition of organs or bodies, which have lost the control on their growth with excessive cell proliferation (Weinberg, 1996; Schmelzle and Hall, 2000; Chan and Steven, 2021). The causative cancer agents are originated with mutual sharing of multiple environment and genetic factors (Knox, 2010; Parsa, 2012; Yadav and Khodke, 2015; Caruso et al., 2021; Singh et al., 2021).

The environmental exposure on inters or intra-cellular are developing cancer gradually. Available preventions may be adopted against the accomplished factors, which are actively involved in disruption of cellular signaling pathways (Yadav and Khodke, 2015; Huang and Ping-Kun, 2020). Major priority is still prevention



of carcinogenic exposures (Anetor et al., 2008; Rudel et al., 2014; Felter et al., 2021), while particular genetic pre-dispositions are more susceptible than others. Like as people with genetic alterations in BRCA1, BRCA2 and p53 locus have lost the abilities to suppress irregular cell growth (Bièche and Lidereau, 1995; Ingvarsson, 1999; Hilton et al., 2002; Narod and Foulkes, 2004; Colonna and Amanda, 2016; Ababou, 2021).

Meanwhile, a number of factors including gene locus, drugs, environment, industrial pollution, chemicals, radiation, food additives, diet, changed life style could be source to contribute in cancer disease process. Even individuals are living in the same environment and in some individual the cancer develop while not in others. The phenomena could be inherited genetic susceptibility for cancer (Douglas and Wildavsky, 1983; Lichtenstein et al., 2000; Hu et al., 2021). Natural chemicals of human diet appear to be major cause of DNA damage (Ames, 1979). In spite of that many studies are emphasizing that cumulative effects of chemicals among the individuals are acting with different path-ways. These chemicals and their related systems among the cells, tissues and organs could be plausibly conspire in the process to induce tumorigenesis and then ultimately into malignancies (Casey et al., 2015; Hu et al., 2015; Narayanan et al., 2015; Mwila et al., 2021).

The electrolyte disturbance might be involved in the mediation of cancerous micro-environment for the pro-carcinogenic outcomes. The role of dysregulation of electrolytes-homeostasis is the most recognized feature, which enable the induction, maintenance and progression of cancer (Woolf et al., 2016; Kamanga and Zhou, 2017; Robey et al., 2017; Diala, 2020). The electrolytes are involved in the regulation of the many intra-cellular systems like as protein synthesis, mutagenesis and oncogenesis. These regulatory intra-cellular metallic Mg, Na, K, Cl, H and Ca ions have specific correlations with physiological and growth rates of the cells. Among the turmeric cells, the elevated concentrations of Na and Cl are observed but Mg and K ions remain normal.

The regulation of Na and Cl concentrations have got prime importance to control their concentrations in both normal and tumor cells (Kopec and Groeger, 1988; Cameron and Smith, 1989; Varghese et al., 2021). It has been considered that many metabolic changes are occurring in cancer diseased organs, while an imbalanced electrolyte character is one of them. The present study is aimed for the careful monitoring of various electrolytes in the serum of cancer patients. As it plays destructive role in cancer prognosis.

MATERIAL AND METHODS

Subjects in the study: In present study, the women participated from Nursing Civil Hospital, Mirpur Khas District are arranged into two groups. The total numbers of subjects were confirmed 45 patients and first group of 21 throat and 24 mouth cancer patients (each group divided into 4 sub-groups with 6-indviduals =

1 replicate). Each individual patient was subjected for clinical as well as biochemical analysis. Here in this study, the confirmed replicates of each category were compared for the subjects reported, ethical clearance for the present study was obtained vide letter Ethical letter No Physiol. / ERI /60 / 08.05.19.

Collection of blood samples: The fresh ten milliliters blood serum samples of selected cancer patients in fasting were collected into standard Vacutainer[®] plain vials [anti-coagulated with EDTA-K₂ (ethylene di-amine tetra-acetic acid-dipotassium] from each participant in the blood diagnostic laboratory. The half of each blood sample was transferred for hematological analysis and other half allowed stand at room temperature to clot. The clotted blood was centrifuged for 15 min at 3,000 rpm for 15 min and plasma/serum used for electrolyte estimation and other different biochemical analysis (Alghamdi et al., 2012; Kumar and Gill, 2018).

Hematological Analysis of Samples: A number of hematological attributes were analyzed in collected blood samples of the patients. The parameters including CBC (complete blood count), hematocrit (HCT), Hb level, mean cell Hb (MCH), MCH concentration (MCHC), mean cell volume (MCV) and red blood cell distribution width were determined with Hematology Analyzer (Model-Advia 2120, Bayer Diagnostics, USA) and the liver marker i.e. alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and creatinine and red cell distribution width (RDW) were determined with Beckman Coulter Automatic Biochemical Analyzer by following their procedure given in the manuals (Harthoorn-Lasthuizen et al., 1999; Bereket et al., 2011; Koster, 2015; Wang et al., 2017; Haq et al., 2018).

Determination of Electrolytes: Before absorption, the samples were digested by taking 0.5 ml sample in glass tubes than 3 ml crucibles (20 ml conc. $\text{HNO}_3 + 40$ ml H_2O_2) added. The mixture was placed at hot plate (90°C) for 2 hrs. When sample color appears a pale-yellow allow it to cool-down and 10 ml 0.2 M HNO₃ added. Its filtrate is used to run on atomic absorption spectrophotometer [Hitachi-Ltd 180-50 (Sr. #. 5721-2) with graphite furnace G-03] and ion selective electrode (ISE) methods (Transasia Bio-Medicals Ltd) for analysis of electrolytes including sodium, magnesium, calcium and chloride (Kamei et al., 1998; Kazi et al., 2006; Yadav and Khodke, 2015).

Statistical Analysis: The present study was comprised on 04 replicates per cancer patient's category. The collected data expressed as mean with standard error (St. Err.) and these analyzed with CoStat (version 3.03) CoHort software (Berkeley, USA). The significant ($p \le 0.05$) mean values further analyzed with Duncan Multiple Range Test (DMRT) at 5 % (d Steel and Torrie, 1986; Behrens, 1997; Johnson and Bhattacharyya, 2019).

RESULTS AND DISCUSSION

The cancer prevalence has been increasing day by day, leading to acute need of care for growing population

and 24 mouth cancer patients (36-42 years aged) were subjected for various biochemical assessments including complete blood counts (CBC), liver functional tests (LFT) and electrolytes (Table 1).

Table 1. Comparative analysis of clinical attributes including electrolytes in patients of mouth and throat cancers to healthy persons.						
#s.	Characters	Reference values	Healthy persons	Cancer patients		F-signif- icance
				Mouth	Throat	
A. Complete blood count (CBC) analysis						
01.	Hb (g/dL)	13.0-18.0	^a 13.93 <u>+</u> 0.281	^b 11.20±0.667	^b 11.53 <u>+</u> 0.599	7.527 ^{ns}
02.	WBC (109/L)	3.50-10.0	^b 8.100±0.158	^a 10.55 <u>+</u> 0.790	^b 12.300±0.579	13.87**
03.	RBC (1012/L)	3.50-5.50	^b 4.855±0.197	^a 5.248±0.449	^b 3.800±0.171	6.235 ^{ns}
04.	HCT (%)	35.0-55.0	^a 36.75±1.461	^b 34.00±1.046	^{bc} 32.38±0.892	3.645 ^{ns}
05.	MCV (fl)	75.0-100	^a 85.90 <u>+</u> 0.938	^{ab} 83.73±2.939	^b 73.40 <u>±</u> 0.660	13.44**
06.	MCH (pg)	25.0-35.0	^a 27.15 <u>+</u> 0.504	^b 23.63±1.250	^{ab} 26.13±0.774	4.083 ^{ns}
07.	MCHC (g/dl)	33.0-38.0	^a 35.25 <u>+</u> 0.841	^{ab} 34.00±0.471	^b 33.13 <u>+</u> 0.507	2.884 ^{ns}
08.	RDW (%)	11.5-15.5	^a 13.21 <u>+</u> 0.121	^b 16.45 <u>+</u> 0.074	^{ab} 15.42±0.147	3.224 ^{ns}
09.	PLT (108/µL)	150-400	^a 253.8±11.24	^b 342.0±14.14	°410.3±9.801	43.74***
10.	NEU (%)	35.0-80.0	^b 62.25 <u>+</u> 2.428	^a 79.75 <u>+</u> 2.496	°79.75 <u>+</u> 2.955	14.67**
11.	LYM (%)	15.0-50.0	^a 31.00±1.472	^b 48.25±1.887	^b 52.50±2.102	28.95***
12.	MO (%)	2.00-10.0	^a 3.250 <u>+</u> 0.479	^b 2.250 <u>+</u> 0.250	^b 2.000±0.000	4.500 ^{ns}
13.	EOS (%)	1.00-6.00	^a 3.000±1.472	^a 2.250±1.887	^a 2.250±2.102	1.929 ^{ns}
14.	BASO (%)	0.00-0.20	^a 0.119±0.013	^b 0.093±0.001	^b 0.087±0.004	5.148 ^{ns}
B. Liver functional tests (LFT)						
01.	ALP (UL-1)	36.0-141	^a 120.5 <u>+</u> 4.444	^b 96.75 <u>+</u> 5.360	°81.50 <u>+</u> 4.330	17.24**
02.	ALT	4.0-38	^a 20.75±1.887	^b 12.75±1.797	^b 15.00±1.225	6.158 ^{ns}
03.	BR (mg dl-1)	0.20-1.2	^a 0.950 <u>+</u> 0.065	°0.825 <u>+</u> 0.144	^b 0.425 <u>+</u> 0.048	8.331 ^{ns}
04.	Urea (mg dl-1)	10.0-40.0	^b 17.63±1.253	^a 56.30 <u>+</u> 2.464	^a 50.00 <u>+</u> 3.536	64.14***
05.	Crt (mg dl ⁻¹)	0.4-1.40	^a 0.880 <u>+</u> 0.149	^a 2.175 <u>+</u> 0.858	^a 1.075 <u>+</u> 0.111	1.899 ^{ns}
C. Electrolyte analysis						
01.	Mg ²⁺ (mg/dL)	1.50-2.10	^b 1.761 <u>+</u> 0.085	^a 2.188 <u>+</u> 0.035	^a 2.228 <u>+</u> 0.049	18.55**
02.	K ⁺ (mmol/L)	3.50-5.0	^a 4.165 <u>+</u> 0.070	^b 4.425 <u>+</u> 0.078	^b 4.458 <u>+</u> 0.077	4.561 ^{ns}
03.	Cl ⁻ (mmol/L)	95-108	^a 101.8±1.071	^b 97.70 <u>+</u> 0.615	^b 97.00 <u>+</u> 0.221	12.84**
04.	Ca²+ (mg/dL)	8.10-10.2	^a 9.248±0.129	^b 8.638±0.098	^b 8.633±0.097	10.56*

CBC: Complete blood count, RBC: Red blood cells, Hb: Hemoglobin, MCV: Mean corpuscular volume, HCT: Hematocrit, MCH: Mean carpuscular hemoglobin, MCHC: Mean corpuscular hemoglobin concentration, RDW: Red cell distribution width; NEU: Neutrophillus, MO: Monocytes, EOS: Eosinophillus, LYM: Lymphocytes, BASO: Basophillus, WBC: White blood cells, PLT: Platelets, ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, BR: Bilirubin, Crt: Creatinine, Mg+2: Magnesium, K+: Potassium, Cl-: Chloride, Ca+2: Calcium.

Note: The data shown in table is mean of four replicates expressed as mean \pm SE. The Duncan's Multiple Range (DMR) test calculated at 0.05 % significance (p <0.05).

As in table 1, results showed that means of red cell indices in both mouth and throat cancer patients likely to MCV (83.73 ± 2.939 fl and 73.40 ± 0.660 fl; $p \le 0.05$), MCH (23.63 ± 1.250 pg and 26.13 ± 0.774 pg; non-significant) (34.00 ± 0.471 pg and 33.13 ± 0.507 pg; non-significant) and MCHC (34.00 ± 0.471 g/dl and 33.13 ± 0.507 g/ dl; non-significant) observed lowered respectively than healthy control person. The mean values of red cell distribution width (RDW) observed higher in the patients than healthy persons but non significantly. The hematological tumors have observed in close relation with malnutrition, changes in microenvironment and disturbances in erythropoiesis, while RDW levels symbolize the functional survival of abnormal RBC (red blood cell) (Mantovani et al., 2008; Lee et al., 2014; Huang et al., 2016; Matsui et al., 2021).

Rana et al.,

From other CBC parameters, the WBCs, lymphocytes and neutrophil showed higher concentrations in both typed cancer patients than healthy controls. Due to a fact that neoplasms are associated neutrophilia, so demarginating neutrophils are normally tumor cells which are occupying the vascular spaces. These are killed by CD8⁺ cytotoxic T-lymphocyte without prior sensitization, while for evading immunity, there is downregulation of class 1 MHC (major histocompatibility complex) molecule's expression (Warren et al., 1994; Swigut et al., 2004; Mwimanzi et al., 2017). There the lymphocyte count observable either elevated or depressed. The platelet counts also found higher in cancer patients than healthy control (Table 1).

From the results of liver function tests, the blood urea is a sensitive indicator of abnormal renal functions. Its levels from control to patients were increased (Chauhan, Yadav, Kaushal, & Beniwal, 2016). The serum creatinine (Crt) level is further considered as more sensitive over urea for kidney function and it is observed increased (p > 0.05) in patients (Devi, 2015). Meanwhile, increased levels of serum uric acid among the cancer patients (Iseki et al., 2001; Zhu and Cao, 2012; Nincevic et al., 2019) associated renal insufficiencies (Hunsicker et al., 1997; Iseki et al., 2001; Rapa et al., 2020). Activities of serum alkaline phosphatase (ALP) observed significantly lower than healthy persons.

In other studies, the observed parameter was found between the normal ranges (Stieber et al., 1992; Van Hoof et al., 1992; Ray et al., 2017). Similar trend in data also observed total bilirubin levels (Liu et al., 2014). For alanine aminotransferase (ALT), data showed lower ALT in both typed cancer patients than healthier ones but between the normal ranges. The ALT is a sensitive indicator but lack in specificity for hepatocellular injury as it is also in muscles and kidneys (Söderberg et al., 2010; Weber et al., 2019).

he data about the serum electrolytes, the Mg²⁺ levels observed significantly higher from the healthy persons (1.761+0.085 mg/dL) in the mouth (2.188+0.035 mg/dL)and throat (2.228±0.049 mg/dL) cancer patients, while non-significant increase in K⁺ level found among the patients. The serum chloride levels in normal healthy controls were 101.8±1.071 mmol/L, whereas 97.70±0.615 mmol/L and 97.00±0.221 mmol/L in mouth and throat cancer patients respectively. The statistically significant low chloride (Cl) levels were observed in serum of cancer patients from healthy controls but values remained within the reference ranges (McAndrew et al., 2021). Alea et al., (2017) group found that serum levels of Ca²⁺ was significantly decreased in patients in comparison to control group (Thompson, 2010; Doshi et al., 2012; Ephraim et al., 2014). The electrolyte imbalance causes additional risk factor in cancer patients. The prior detection of electrolyte levels night be helpful for the clinicians to manage the cancer prognosis and their proper monitoring (Berghmans et al., 2000; Capdevila et al., 2018; Fassnacht et al., 2018).

CONCLUSION

We have concluded in present study that the imbalanced attributes of CBC, LFTs and electrolyte contents impose additional health risk factors in cancer patients. Their prior detection among the patients might be helpful for the clinicians to manage the cancer prognosis and their proper monitoring. This study of bio-content's analysis may be a helpful diagnostic tool in terms of minimizing the imbalanced characters in patients with different supplements.

ACKNOWLEDGEMENTS

Authors are very thankful to acknowledge, the financial support from University as well as help by non-teaching technical staff of laboratory.

Conflict of Interest: No conflict of interest declared.

REFERENCES

Ababou, M., (2021). Bloom syndrome and the underlying causes of genetic instability. Molecular Genetics and Metabolism , 133(1), pp 35-48.

Alghamdi, L., Tarabah, L. N., Nouf, L., Alshereef, L., and Alghazzawi, L. W. (2012). Liver Function Tests. Clinical Biochemistry Lab Mannual.

Ames, B. N. (1979). Identifying environmental chemicals causing mutations and cancer. Science, 204(4393), pp 587-593.

Anetor, J., Anetor, G., Udah, D., and Adeniyi, F. (2008). Chemical carcinogenesis and chemoprevention: scientific priority area in rapidly industrializing developing countries. African Journal of Environmental Science and Technology, 2(7), pp 150-156.

Ashaq, A., Muhammad, F. M., Amara, M., Muhammad. K., Hafiz, A. S., Muhammad, I., Javed, I. Q., Yongming, L., and Tonghui, M., (2021). Hispidulin: A novel natural compound with therapeutic potential against human cancers. Phytotherapy Research, 35(2), pp 771-789.

Begum, N., Nasreen, S., and Shah, A. S. (2012). Quantification of trends in radiation oncology infrastructure in Pakistan, 2004–2009. Asia-Pacific Journal of Clinical Oncology, 8(1), pp 88–94.

Behrens, J. T. (1997). Principles and procedures of exploratory data analysis. Psychological Methods, 2(2), pp 131-160.

Bereket, A., Akçay, T., Omar, A., Atay, Z., Güran, T., Gökçe, I., Güran, T., Atay, Z., Omar, A., Akçay, T., and Turan, S. (2011). Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. Journal Of Clinical Research in Pediatric Endocrinology, 3(1), pp 7-11.

Berghmans, T., Paesmans, M., and Body, J.-J. (2000). A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Supportive Care in Cancer, 8(3), pp 192-197.

Bièche, I., and Lidereau, R. (1995). Genetic alterations in breast cancer. Genes, Chromosomes and Cancer, 14(4), pp 227-251.

Cameron, I., and Smith, N. (1989). Cellular concentration of magnesium and other ions in relation to protein synthesis, cell proliferation and cancer. Magnesium, 8(1), pp 31-44.

Cao, B., Bray, F., Beltrán-Sánchez, H., Ginsburg, O., Soneji, S., and Soerjomataram, I. (2017). Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. British Medical Journal, 357, pp j2765. doi: 10.1136/bmj.j2765.

Capdevila, J., Kate N., Lisa L., Aron P., Francesc M., José Z., Michael K., Javier A., and Enrique G., (2018). Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews, 69. pp 164-176.

Caruso, S., Daniel, R. O'B., Sean, P. C., Lewis, R. R., and Jessica, Z.-R., (2021). Genetics of hepatocellular carcinoma: Approaches to explore molecular diversity. Hepatology, 73, pp 14–26.

Casey, S. C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., Forte, S., Hamid, R. A., Heneberg, P., Koch, D. C., Krishnakumar, P. K., Laconi, E., Maguer-Satta, V., Marongiu, F., Memeo, L., Mondello, C., Raju, J., Roman, J., Roy, R., Ryan, E. P., Ryeom, S., Salem, H. K., Scovassi, Singh, A. I., Soucek, L., Vermeulen, L., Whitfield, J. R., Woodrick, J., Colacci 1, A. M. Bisson, W. H., and Curran, C. S. (2015). The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis, 36(Suppl_1), pp S160-S183.

Chan, A. M., and Steven F., (2021). Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Medicinal Chemistry, 12(2), pp 178-196.

Chauhan, P., Yadav, R., Kaushal, V., and Beniwal, P. (2016). Evaluation of serum biochemical profile of breast cancer patients. International Journal of Medical Research & Health Sciences, 5(7), pp 1-7.

Colonna, S., and Amanda, G., (2016). Management of the patient with a genetic predisposition for breast cancer. In Management of Breast Diseases, pp 575-592, Springer, Cham.

d Steel, R. G., and Torrie, J. H. (1986). Principles and procedures of statistics: a biometrical approach: McGraw-Hill.

Devi, L. I. R., L. and Ali, M.A. (2015). Serum biochemical profile of breast cancer patients. European Journal of Pharmaceutical and Medical Research, 2(6), pp 210-214.

Diala, K., (2020). Functional study of the MAGI1 scaffold protein and the Hippo pathway involvement in luminal breast and colorectal cancers. Ph.D., Thesis. Agricultural Sciences. Université Montpellier, NNT : 2020MONTT050. Douglas, M., and Wildavsky, A. (1983). Risk and culture: An essay on the selection of technological and environmental dangers: Univ of California Press.

Elshaygi, E. A., Dafaala, A. A., and Bakheet, A. O. (2017). Assessment of Serum Level of Electrolytes and Trace Elements in Leukaemia Patients in Sudan. Sudan Journal of Science and Technology, 18(1), pp 26-32.

Elshaygi, E. A. A. (2017). Assessment of Serum Electrolytes and Trace Elements in Leukaemia Patients in Sudan. Ph.D., Thesis, Sudan University of Science and Technology.

Ephraim, R. K. D., Osakunor, D. N. M., Denkyira, S. W., Eshun, H., Amoah, S., and Anto, E. O., (2014). Serum calcium and magnesium levels in women presenting with pre-eclampsia and pregnancy-induced hypertension: a case-control study in the Cape Coast metropolis, Ghana. BMC pregnancy and childbirth, 14(1), pp 1-8.

Fassnacht, M., Olaf M. D., Tobias E., Eric B., Alfredo B., Ronald R. D. K., Harm R. H., Radu M., Guillaume A., and Massimo T., (2018). European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors. European Journal of Endocrinology, 179(4), pp G1-G46.

Felter, S. P., Xiaoling, Z, and Chad, T., (2021). Butylated Hydroxyanisole: Carcinogenic food additive to be avoided or harmless antioxidant important to protect food supply?. Regulatory Toxicology and Pharmacology, 121, pp 104887. doi: 10.1016/j.yrtph.2021.104887.

Hanif, M., Zaidi, P., Kamal, S., and Hameed, A. (2009). Institution-based cancer incidence in a local population in Pakistan: nine year data analysis. Asian Pacific Journal of Cancer Prevention, 10(2), pp 227-230.

Haq, I.-U., Kumar, D., Hussain, S., Mirza, M. R., Hameed, A., and Gill, N. P. (2018). Comparative study of β -thalassemia major among the patients from urban and rural population in Hyderabad region. International Journal of Biosciences, 12(3), pp 224-234. doi: http:// dx.doi.org/10.12692/ijb/12.3.224-234

Harthoorn-Lasthuizen, E., Lindemans, J., and Langenhuijsen, M. C. (1999). Influence of iron deficiency anaemia on haemoglobin A2 levels: possible consequences for B? thalassaemia screening. Scandinavian Journal of Clinical and Laboratory Investigation, 59(1), pp 65-70.

Hilton, J. L., Geisler, J. P., Rathe, J. A., Hattermann-Zogg, M. A., DeYoung, B., and Buller, R. E. (2002). Inactivation of BRCA1 and BRCA2 in ovarian cancer. Journal of the National Cancer Institute, 94(18), pp 1396-1406.

Hu, Z., Brooks, S. A., Dormoy, V., Hsu, C.-W., Hsu, H.-Y., Lin, L.-T., Massfelder, T., Rathmell, W. K., Xia, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Brown, D. G., Prudhomme, K. R., Colacci, A. M., Hamid, R. A., Mondello, C., Raju1, J., Ryan, E. P., Woodrick, J., Scovassi, I., Singh, N., Vaccari, M., Roy, R., Forte, S., Memeo, L., Salem, H. K., Lowe, L., JensenL., Bisson, W. H., and Al-Mulla, F. (2015). Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis, 36(Suppl_1), pp S184-S202.

Hu, C., Steven, N. H., Rohan, G., Hongyan, H., Kun, Y. L., Jie, N., Chi, G. et al. (2021). A population-based study of genes previously implicated in breast cancer. New England Journal of Medicine, 384(5), pp 440-451.

Huang, D.-P., Rui-Min, M., and You-Qun, X., (2016). Utility of red cell distribution width as a prognostic factor in young breast cancer patients. Medicine, 95(17), pp e3430.

Huang, R.-X., and Ping-Kun Z., (2020). DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduction and Targeted Therapy, 5(1), pp 1–27.

Hunsicker, L. G., Adler, S., Caggiula, A., England, B. K., Greene, T., Kusek, J. W., Nancy, R., and Beck, G. (1997). Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney International, 51(6), pp 1908-1919. doi: 10.1038/ki.1997.260.

Ingvarsson, S. (1999). Molecular genetics of breast cancer progression. Seminars in Cancer Biology 9(4), pp 277-88.

Iseki, K., Oshiro, S., Tozawa, M., Iseki, C., Ikemiya, Y., and Takishita, S. (2001). Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Research, 24(6), 691–697. doi: 10.1291/hypres.24.691

Jemal, A., Center, M. M., DeSantis, C., and Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology and Prevention Biomarkers, 19(8), pp 1893-1907.

Johnson, R. A., & Bhattacharyya, G. K. (2019). Statistics: principles and methods: John Wiley & Sons.

Kamanga, N. E., and Zhou, D. T. (2017). Serum magnesium levels in cervical cancer patients on cisplatin based chemotherapy at parirenyatwa group of hospitals, zimbabwe. Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences 3(3), pp 115-123. DOI – 10.26479/2017.0303.08

Kamei, K., Tabata, O., Muneoka, K., Muraoka, S. I., Tomiyoshi, R., and Takigawa, M. (1998). Electrolytes in erythrocytes of patients with depressive disorders. Psychiatry and Clinical Neurosciences, 52(5), pp 529-533.

Kazi, T. G., Jamali, M. K., Siddiqui, A., Kazi, G., Arain, M., and Afridi, H. (2006). An ultrasonic assisted extraction method to release heavy metals from untreated sewage sludge samples. Chemosphere, 63(3), pp 411-420.

Knox, S. S. (2010). From'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell International, 10(1), pp 1-13. Kopec, I. C., and Groeger, J. S. (1988). Life-threatening fluid and electrolyte abnormalities associated with cancer. Critical care clinics, 4(1), pp 81-105.

Koster, R. A. (2015). The influence of the sample matrix on LC-MS/MS method development and analytical performance. University of Groningen.

Kumar, V., and Gill, K. D. (2018). Basic Concepts in Clinical Biochemistry: A Practical Guide: Springer.

Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., Hemminki, K. (2000). Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. New England Journal of Medicine, 343(2), pp 78-85.

Liu, Z., Ning, H., Que, S., Wang, L., Qin, X., and Peng, T. (2014). Complex association between alanine aminotransferase activity and mortality in general population: a systematic review and meta-analysis of prospective studies. PloS One, 9(3), pp e91410.

Matsui, H., Taniguchi, Y., Maru, N., Utsumi, T., Saito, T., Hino, H., & Murakawa, T., (2021). Prognostic effect of preoperative red cell distribution width on the survival of patients who have undergone surgery for non-small cell lung cancer. Molecular and Clinical Oncology, 14(5), pp 1–7. https://doi.org/10.3892/mco.2021.2270

McAndrew, N. P., Bottalico, L., Mesaros, C., Blair, I. A., Tsao, P. Y., Rosado, J. M., Ganguly, T., Song, S. J., Gimotty, P. A., Mao, J. J., and DeMichele, A., (2021). Effects of systemic inflammation on relapse in early breast cancer. NPJ Breast Cancer, 7(1), pp.1-10.

Moore, M. A. (2013). What and where for publications by cancer registries in the Asian Pacific?: roles for the APJCP in the future. Asian Pac J Cancer Prev, 14(8), pp 4939-4942.

Murray, C. J. L., Aleksandr, Y. A., Peng, Z., Cristiana, A., Kaja, M. A., Mohsen, A.-K., Foad, A.-A. et al., (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396 (10258), pp 1223-1249.

Mwila, K., Stuart, D., Gilad, B., Joseph, T., (2021). Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?, FEMS Microbiology Reviews, 2021, fuab017, https://doi. org/10.1093/femsre/fuab017

Mwimanzi, F., Toyoda, M., Mahiti, M., Mann, J. K., Martin, J. N., Bangsberg, D., Brockman, M. A., Goulder, P., Kirchhoff, F., Brumme, Z. L., Ndung'u, T., Ueno, T., (2017). Resistance of major histocompatibility complex class B (MHC-B) to Nef-mediated downregulation relative to that of mhc-a is conserved among primate lentiviruses and influences antiviral T cell responses in HIV-1-infected individuals. Journal of Virology, 92(1), pp 01409-17. doi: 10.1128/JVI.01409-17. PMID: 29046444; PMCID: PMC5730772.

Narayanan, K. B., Ali, M., Barclay, B. J., Cheng, Q.,

D'Abronzo, L., Dornetshuber-Fleiss, R., Ghosh, P.M., Gonzalez Guzman, M.J., Lee, T.J., Leung, P.S. and Li, L., (2015). Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis, 36(Suppl_1), pp S89-S110.

Narod, S. A., and Foulkes, W. D. (2004). BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer, 4(9), pp 665-676.

Nincevic, V., Omanovic Kolaric, T., Roguljic, H., Kizivat, T., Smolic, M., and Bilic curcic, I., (2019). Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. International Journal of Molecular Sciences, 20(23), pp 5831.

Parsa, N. (2012). Environmental factors inducing human cancers. Iranian journal of public health, 41(11), 1-9.

Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., and Marzocco, S., (2020). Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived metabolites. International journal of molecular sciences, 21(1), pp 263.

Ray, C. S., Singh, B., Jena, I., Behera, S., and Ray, S., (2017). Low alkaline phosphatase (ALP) in adult population an indicator of zinc (Zn) and magnesium (Mg) deficiency. Current Research in Nutrition and Food Science Journal, 5(3), pp 347-352.

Robey, R. B., Weisz, J., Kuemmerle, N., and Bisson, W. H. (2017). Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? Carcinogenesis, 36(Suppl 1), pp S203-S231. doi:10.1093/carcin/bgv037.

Rudel, R. A., Ackerman, J. M., Attfield, K. R., and Brody, J. G. (2014). New exposure biomarkers as tools for breast cancer epidemiology, biomonitoring, and prevention: a systematic approach based on animal evidence. Environmental health perspectives, 122(9), pp 881-895.

Schmelzle, T., and Hall, M. N. (2000). TOR, a central controller of cell growth. Cell, 103(2), pp 253-262.

Simard, E. P., Ward, E. M., Siegel, R., and Jemal, A. (2012). Cancers with increasing incidence trends in the United States: 1999 through 2008. Cancer Journal for Clinicians, 62(2), pp 118-128.

Singh, U., Kyle, M. H., Bruce, J. A., and Eve, S. W., (2021). African Americans and European Americans exhibit distinct gene expression patterns across tissues and tumors associated with immunologic functions and environmental exposures. Scientific reports 11(1), pp 1-14.

Stieber, P., Nagel, D., Ritzke, C., Rössler, N., Kirsch, C. M., Eiermann, W., and Fateh-Moghadam, A. (1992). Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma. European Journal of Clinical Chemistry and Clinical Biochemistry, 30, pp 809-814.

Swigut, T., Alexander, L., Morgan, J., Lifson, J., Mansfield, K.G., Lang, S., Johnson, R.P., Skowronski, J. and Desrosiers, R., 2004. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. Journal of Virology, 78(23), pp.13335-13344.

Torre, L. A., Siegel, R. L., Ward, E. M., and Jemal, A. (2016). Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers, 25(1), pp 16-27.

Van Hoof, V. O., Van Oosterom, A. T., Lepoutre, L. G., and De Broe, M. E. (1992) Alkaline phosphatase isoenzyme patterns in malignant disease. Clinical Chemistry, 38(12),, pp 2546-2551.

Varghese, E., Samson, Mathews, S., Zuhair, S., Peter, K., Alena, L., Jozef, B., P. P., Peter, K., and Dietrich, B., (2019). Anti-cancer agents in proliferation and cell death: the calcium connection. International Journal of Molecular Sciences, 20(12), pp 3017. https://doi.org/10.3390/ijms20123017.

Wang, H. B., Wang, Q. Y., Yuan, Q., Shan, X. Y., and Fu, G. H. (2017). Alanine aminotransferase is more sensitive to the decrease in hepatitis B virus-DNA load than other liver markers in chronic hepatitis B patients. Journal of Clinical Laboratory Analysis, 31(6), pp e22141.

Warren, A. P., Ducroq, D. H., Lehner, P. J., and Borysiewicz, L. K. (1994). Human cytomegalovirusinfected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. Journal of Virology, 68(5), pp 2822-2829.

Weber, S., Benesic, A., Rotter, I., and Gerbes, A. L., (2019). Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver International, 39(10), pp 1906-1917.

Weinberg, R. A. (1996). How cancer arises. Scientific American, 275(3), pp 62-70.

Woolf, E. C., Syed, N., and Scheck, A. C. (2016). Tumor metabolism, the ketogenic diet and β -hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Frontiers in Molecular Neuroscience, 9, pp 122. https:// doi.org/10.3389/fnmol.2016.00122.

Yadav, A. S., and Khodke, P. V. (2015). Status of serum electrolytes in cancer patients. International Journal of Basic and Applied Medical Sciences, 5, pp 208-211.

Zhu, H.-C., and Cao, R.-l. (2012). The relationship between serum levels of uric acid and prognosis of infection in critically ill patients. World Journal of Emergency Medicine, 3(3), pp 186-190.